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We have used homologous recombination to disrupt the mouse
gene coding for the NaK2Cl cotransporter (NKCC2) expressed in
kidney epithelial cells of the thick ascending limb and macula
densa. This gene is one of several that when mutated causes
Bartter’s syndrome in humans, a syndrome characterized by severe
polyuria and electrolyte imbalance. Homozygous NKCC22y2 pups
were born in expected numbers and appeared normal. However,
by day 1 they showed signs of extracellular volume depletion
(hematocrit 51%; wild type 37%). They subsequently failed to
thrive. By day 7, they were small and markedly dehydrated and
exhibited renal insufficiency, high plasma potassium, metabolic
acidosis, hydronephrosis of varying severity, and high plasma renin
concentrations. None survived to weaning. Treatment of 2y2 pups
with indomethacin from day 1 prevented growth retardation and
10% treated for 3 weeks survived, although as adults they exhib-
ited severe polyuria (10 mlyday), extreme hydronephrosis, low
plasma potassium, high blood pH, hypercalciuria, and proteinuria.
Wild-type mice treated with furosemide, an inhibitor of NaK2Cl
cotransporters, have a phenotype similar to the indomethacin-
rescued 2y2 adults except that hydronephrosis was mild. The
polyuria, hypercalciuria, and proteinuria of the 2y2 adults and
furosemide-treated wild-type mice were unresponsive to inhibi-
tors of the renin angiotensin system, vasopressin, and further
indomethacin. Thus absence of NKCC2 in the mouse causes poly-
uria that is not compensated elsewhere in the nephron. The NKCC2
mutant animals should be valuable for uncovering new patho-
physiologic and therapeutic aspects of genetic disturbances in
water and electrolyte recovery by the kidney.
gene targeting u NaK2Cl cotransporter u nonsteroidal anti-inflammatory
drug u hydronephrosis
Bartter’s syndrome, characterized by hypokalemic metabolicalkalosis, hyperreninemia, polyuria, and dehydration (1),
includes several disorders of water and electrolyte handling by
the kidney that share many physiologic derangements but differ
in others (2, 3). Classic Bartter’s syndrome is characterized by
onset during infancy or early childhood, delayed growth, poly-
uria, hypokalemia, hyperreninemia, hypercalciuria, and high
prostaglandin (PG) excretion in the urine (3). An antenatal
variant exhibits a more severe phenotype, prematurity, hydram-
nios, massive polyuria, life-threatening episodes of dehydration,
growth retardation, very high urinary PG, and calcium excretion
and nephrocalcinosis (3–5). Gitelman’s syndrome, although sim-
ilar to Bartter’s syndrome, is more frequent and differs in
showing hypomagnesemia, hypocalciuria, normal urinary PG,
and onset during childhood or adolescence (2, 6). Defects in
genes coding for three proteins expressed in the thick ascending
limb of Henle’s loop of the kidney—the NKCC2 NaK2Cl
cotransporter (7), the CLCNKB chloride channel (8), and the
ROMK potassium channel (9)—have been implicated as causing
antenatal Bartter’s syndrome. Our present work is concerned
with NKCC2.
The kidney-specific NaK2Cl cotransporter (NKCC2 or BSC1)
(10, 11) is strongly expressed on the luminal membrane of renal
tubular epithelial cells of the thick ascending limb of Henle’s
loop (12, 13), where it is essential for normal Na, K, Cl, Ca, and
Mg reabsorption (14) and for the maintenance of the cortico-
medullary osmotic gradient, a key element in the urine concen-
trating mechanism (14). NKCC2 also is expressed in the spe-
cialized cells of the distal tubules that constitute the macula
densa (15, 16). Macula densa cells sense the chloride concen-
tration of the fluid in the adjacent lumen and, depending on this
concentration, control the filtration rate of the connected up-
stream glomerulus (a mechanism known as tubuloglomerular
feedback). In addition, the macula densa controls the secretion
of renin from nearby juxtaglomerular cells (17). The signaling
mechanism is not well understood.
To provide an animal model in which the complex pathophys-
iology of Bartter’s syndrome can be related to the distribution
and ionic functions of the NKCC2 cotransporter, we have used
homologous recombination to inactivate the gene (Slc12a1) that
codes for this protein in mice. The resulting mice have many
similarities to humans with Bartter’s syndrome.
Materials and Methods
Generation of Mutant Mice. The NKCC2 gene was cloned from a
strain 129ySvEvTac murine genomic DNA library. Gene tar-
geting, as described (18), was used to disrupt the NKCC2 gene.
The targeting plasmid, illustrated in Fig. 1a, was electroporated
into the TC-1 embryonic stem cell line (19) derived from mouse
strain 129ySvEvTac FBR. Targeting was confirmed by Southern
blot analysis of cell DNA digested with BamHI and hybridized
to probe a (Fig. 1a). Targeted clones have a 7.2-kb band in
addition to an 18-kb endogenous band. Male chimeras carrying
the disrupted allele were mated with 129ySvEv females to obtain
animals with a genetically uniform background. Mice were
handled by following the National Institutes of Health guidelines
for the use and care of experimental animals.
Genotyping. Genotypes were determined by PCR with primers b,
59-CTTCTATCGCCTTCTTGACG-39; c, 59-GCATCTT-
TACTCTTGGGAGC-39; and d, 59-CAATAGGCTGCT-
GAGATGAG-39 (Fig. 1a). The presence of a 490-bp fragment,
a 620-bp fragment, or both fragments identifies animals with the
2y2, 1y1, and 1y2 genotypes, respectively.
Indomethacin Protocol. Subcutaneous injection of indomethacin
(Sigma, 6 mgyg body weight, once a day) to all pups regardless
of genotypes was started at 1 day after birth and continued for
3 weeks or until prior sacrifice.
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Vasopressin Protocol. Mice were given water containing 5%
dextrose for 3 days before the experiment to ensure production
of a relatively dilute urine. On the experimental day, urine was
collected and 1 ngyg body weight of [desamino-Cys1, D-Arg8]
vasopressin (DDAVP, desmopressin, Sigma) was injected i.p.
Urine osmolality was measured at 1 and 2 h after the injection.
Analyses of Blood and Plasma Renin Concentration. Blood samples
were analyzed with a VT250 Chemical Analyzer (Johnson &
Johnson) and Cobas Micro Hematology Analyzer (Roche Di-
agnostics). Plasma renin concentration was measured as de-
scribed (20).
Analyses of Urine and Kidney Function. Mice were maintained on a
12-h lightydark cycle and given water and food ad libitum. Body
weight, amount of water and food intake, and urine excretion
were measured every 24 h for 3 days. Osmolality of the urine and
excretion of electrolyte and protein were measured (VT250
Chemical Analyzer) and normalized to a 20 g body weight.
Urinary excretion of PGE2 was assayed with the PGE2 EIA
system, RPN 222 (Amersham Pharmacia Biotech).
SDSyPAGE of Plasma and Urine Proteins. Samples were preheated
with b-mercaptoethanol for 5 min at 95°C, electrophoresed on
a 4–15% gradient TriszHCl SDS-polyacrylamide gel (Bio-Rad),
and stained with Coomassie brilliant blue.
Western Blot Analyses. Antibody against NKCC2 was a gift from
Mark A. Knepper, (National Institutes of Health, Bethesda,
MD), and was used as described (12).
Microscopy, Renin Immunohistochemistry, and Morphometric Analy-
sis. Immunohistochemistry for renin in kidney sections was
performed as described (21, 22). Hydronephrosis was recorded
for each kidney section as the percentage area of the pelvis
relative to the total cross sectional area.
Statistics. All values are expressed as mean 6 SEM. Student’s t
test and tests of Pearson’s correlation coefficient were used for
statistical evaluations.
Results and Discussion
NKCC2 Mutant Mice. Mice carrying a null allele of NKCC2 were
generated from embryonic stem cells by deleting 12 kb of DNA
that includes the promoter of the gene and exons 1–3 (Fig. 1a).
Matings between 1y2 heterozygotes produced 1y1, 1y2,
and 2y2 pups at the expected Mendelian ratios at birth (27
1y1, 49 1y2, and 24 2y2). Western blot analysis of kidney
proteins showed that NKCC2 expression is absent in the 2y2
mice (Fig. 1b). Although hydramnios is common in human
neonatal Bartter’s syndrome (23), there was no obvious polyhy-
dramnios during pregnancy in the 2y2 fetuses. Inspection of
pups within 24 h after birth likewise revealed no obvious
differences in appearance or body weight among the three
genotypes. However, even by day 1, the 2y2 mice already
showed signs of extracellular fluid volume depletion as judged by
their hematocrits (50.8 6 3.6% versus 37.0 6 0.7% in wild type,
n 5 6, P , 0.01). By 7 days of age, the homozygotes were easily
identified because of their poor turgor and wrinkled skin caused
by fluid loss (Fig. 1c) and failure to thrive (body weight, on day
7, 3.2 6 0.2 g versus 6.2 6 0.4 g in wild type, n 5 6, P , 0.0001).
The 2y2 mice died within 2 weeks (Fig. 1d), and none of more
than 100 2y2 pups survived to weaning without treatment.
Blood Chemistry and Kidneys in 7-Day-Old NKCC22y2 Pups. When
mixed arterial and venous blood was collected at 7 days of age
by decapitation, the NKCC22y2 mice proved significantly
different from wild type in all parameters measured (Table 1).
Fig. 1. Targeted inactivation of the NKCC2 gene and analysis of NKCC22y2
pups. (a) Gene targeting strategy. (Top) The region of the NKCC2 gene extending
from the promoter to intron 4. (Exon 4 has three parts, 4B, 4A, and 4F.) (Middle)
Targeting construct. (Bottom) Targeted allele in which the gene is disrupted and
12 kb from 2.5 kb upstream of transcription initiation site to part of intron 3 is
replaced with the neomycin resistance gene, Neo. TK, Herpes simplex virus-
thymidine kinase gene. 1–4 are exons 1–4. Restriction sites are B, BamHI; N, NheI.
The positions of probe a and primers b–d are indicated. (b) Western blot analysis
of kidney homogenate from 1y1 and 2y2 mice. The blot was exposed to
anti-NKCC2 antibody. (c) Growth retardation and poor turgor of 2y2 mice.
Wild-type (1y1) (Left) and homozygous mutant mouse (2y2) (Right) from the
same litter at 7 days after birth. (d) Mortality rate of 2y2 mice and control mice,
1y1 and 1y2. Dead animals were collected daily and genotyped. 1y1, n 5 15;
1y2, n 5 25; 2y2, n 5 13. (e) Kidneys from 1y1 and 2y2 mice at 7 days of age
stained with hematoxylin and eosin. (Original magnification: 31.) (f) Correlation
betweenseverityofhydronephrosisandbodyweightof7-day-old2y2pups.n5
19, correlation coefficient 0.7269, R2 5 0.528, P , 0.0001. (g–i) Renin immuno-
histochemistry with kidney sections from 7-day-old pups. (g) Renin staining
(brown) is confined to the afferent arterioles in 1y1. (h and i) Renin staining
includes afferent arterioles and extends along them in the direction of the
interlobular arteries. Efferent arterioles and glomeruli are also renin positive.
(Original magnification: 3200.)











Of these, the higher hematocrit, Na, Cl, and total protein are
indicative of a dehydration. In contrast, total plasma Ca was
significantly less than normal, as was ionized Ca (2.9 6 0.3 mgydl
versus 4.9 6 0.1 mgydl in wild type, n 5 5, P , 0.0001). Plasma
creatinine of the 2y2 pups was about three times wild type.
However, because their body weights were about half wild type,
creatinine normalized by muscle mass would be much higher,
indicating severe renal insufficiency. The 2y2 pups had an
impaired ability to concentrate their urine as judged by its
osmolality even in the setting of dehydration (370 6 7 mOsm vs.
420 6 25 mOsm in wild type, n 5 6, P , 0.01). Different from
adult mice (see below), the concentration of urine protein in the
2y2 and 1y1 pups was very low, often below a detectable level
(,5 mgydl). The 2y2 pups had higher plasma K and lower
HCO3 than normal. They exhibited metabolic acidosis associ-
ated with an elevated anion gap, Na-(Cl 1 HCO3). Some human
patients with Bartter’s syndrome also exhibit metabolic acidosis
(24, 25).
The 2y2 pups showed bilateral hydronephrosis of varying
severity, as judged by an abnormal dilatation of the renal
collecting system (pelvis and calyx) with different degrees of
atrophy of the renal parenchyma (Fig. 1e). This hydronephrosis
was sometimes present as early as at term in utero. We observed
a positive correlation between the severity of hydronephrosis
and body weight (Fig. 1f ). This correlation was still observed
when kidney weight was subtracted from the body weight. The
stomachs of the 2y2 pups were frequently empty, and their
blood glucose concentration was low (Table 1), whereas the
stomachs of the 1y1 and 1y2 pups were always full of milk.
It is possible that some of the 2y2 pups compete better for milk,
grow better, and excrete more urine, causing more severe
hydronephrosis. It is also possible that the hydronephrosis
protects against f luid loss by decreasing glomerular filtration.
The frequently empty stomachs of the 2y2 pups indicated
inadequate nutrition compared with the wild type and heterozy-
gous litter mates and probably led to their dehydration and early
death.
Distribution of Renin. Immunohistochemistry of the 2y2 kidneys
showed a very marked increase in the expression of renin along
the afferent arterioles and interlobular arteries, in the intraglo-
merular region, and along the efferent arterioles (Fig. 1 g–i); this
is consistent with the 2003 normal plasma renin concentration
of the mutants (Table 1). This distribution of renin strongly
resembles that seen in human Bartter’s syndrome (1). The cause
of the extremely high plasma renin concentration is an increase
in the proportion of vascular smooth muscle cells, pericytes, and
mesangial cells that produce renin (26). This increase most likely
occurs because the macula densa cells transduce a signal falsely
indicating a very low amount of chloride in the lumen (17, 27),
and because dehydration and volume depletion (1, 28) diminish
the stretch of the arterioles.
Rescue of NKCC22y2 Pups. We first attempted to correct the
dehydration and volume depletion of the 2y2 pups by s.c.
injection of 0.45% saline (100 mlyg body weight, once a day).
Survival was not improved. Human patients with prenatal
Bartter’s syndrome show an increased synthesis of PGE2
throughout the body (29, 30), and cyclooxygenase (COX) inhib-
itors have commonly been used for their treatment. In some
patients this treatment reduces urine volume and urinary excre-
tion of calcium and improves growth (31–33). Given these
findings, we s.c. injected 6 mgyg per day of indomethacin, a
potent nonselective COX inhibitor, into neonatal mice of all
three genotypes starting at day 1 after birth and continuing until
3 weeks of age.
By day 7, the indomethacin treatment caused a 2-fold decrease
in plasma renin concentration in the 1y1 and the 2y2 mice,
from 127.6 6 47.8 ng angiotensin (Ang) Iyml per h to 77.8 6 9.7
ng Ang Iyml per h and from 25,700 6 1,840 ng Ang Iyml per
h to 13,000 6 745 ng Ang Iyml per h (P , 0.0001). We could not
use higher doses of indomethacin because of frequent stomach
perforation. Some of the indomethacin-treated 2y2 mice, when
killed at 7 days of age, were indistinguishable from wild type in
body weight, plasma Na, K, Cl, and Cr, but they all developed
hydronephrosis. Indomethacin enabled survival of some 2y2
mice to weaning at 3 weeks, but most (74y83, 90%) died. The
surviving weanlings showed a catch-up growth that continued
after indomethacin was no longer given. The turgor of the
surviving 2y2 mice was not distinguishable from wild type.
Almost half of these surviving indomethacin-treated 2y2 wean-
lings have lived more than 10 months, but all developed extreme
bilateral hydronephrosis, leading to a massively enlarged, paper-
thin kidney with a greatly dilated calyx and pelvis and an almost
completely destroyed medulla (Fig. 2a). The cortex was dimin-
ished to a very thin rim. The tubules were focally dilated (Fig.
2b). The severe hydronephrosis in the surviving 2y2 adults is
most likely because the flow of dilute urine in these animals
exceeds the maximum capability of the ureter and causes exces-
Table 1. Blood data of 7-day-old pups
NKCC2 genotype
1y1 2y2
pH 7.49 6 0.01 7.29 6 0.04*
HCO3, mmolyliter 27.3 6 1.0 13.3 6 1.0*
Base excess, mmolyliter 3.2 6 1.0 211.8 6 1.5*
Lactate, mmolyliter 2.6 6 0.1 4.1 6 0.2*
pCO2, mmHg 39.0 6 1.5 27.3 6 0.8*
Glucose, mgydl 168.6 6 9.7 81.0 6 8.5†
Hematocrit, % 37.0 6 0.5 46.6 6 0.7†
Na, mmolyliter 131.9 6 0.5 163.7 6 3.6*
K, mmolyliter 6.1 6 0.4 7.2 6 0.1‡
Cl, mmolyliter 100.3 6 1.1 117.0 6 3.2*
Ca, mgydl 10.7 6 0.2 9.1 6 0.7†
Mg, mgydl 2.3 6 0.04 3.1 6 0.06*
Total protein, mgydl 3.2 6 0.1 3.9 6 0.5†
Creatinine, mgydl 0.35 6 0.03 0.90 6 0.17*
BUN, mgydl 28.2 6 3.3 194.3 6 60.7*
PRC, ng Ang Iyml per h 127.6 6 47.8 25,700 6 1,840*
Data are means 6 SEM. n . 6. pCO2, CO2 pressure; BUN, blood urea
nitrogen; PRC, plasma renin concentration.
*P vs. 1y1 , 0.0001.
†P vs. 1y1 , 0.005.
‡P vs. 1y1 , 0.05.
Fig. 2. Analysis of NKCC22y2 adult mice. (a) Kidneys from 1y1 and 2y2
mice of the same litter at 5 months of age. Mice were treated with indometh-
acin to 3 weeks of age. (b) Kidney from 2y2 mouse 5 months of age stained
with hematoxylin and eosin. *, Calcification in tubules. Note the focal dilata-
tion of tubules. (Original magnification: 3100.) (c) Analysis of plasma and
urine proteins from mice at 3 months of age. Lane 1, plasma from a wild-type
male (1 ml); lane 2, plasma from a NKCC22y2 male (1 ml); lane 3, urine from
a 2y2 female (20 ml of 53 concentrate); lane 4, urine from a 2y2 male
(15 ml).
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sive pressure in the renal pelvis. In contrast, the kidneys from
wild-type mice treated with indomethacin until 3 weeks after
birth were indistinguishable from the kidneys of untreated
wild-type mice.
BloodyUrine Chemistry in Surviving NKCC22y2 Adult Mice. Venous
blood drawn from the retroorbital sinus of the 2y2 indomethacin-
treated survivors at 3 months of age showed lower K, but pH and
HCO3 were significantly above wild type (Table 2). Although the
2y2 mice that survived to weaning after 3 weeks of indomethacin
had unlimited access to water and food and no longer had poor
turgor, they had an extremely high hematocrit (70%) and a very
high plasma renin concentration (Table 2), suggesting that they
were still appreciably dehydrated. We do not know whether the high
hematocrit is solely because of a decrease in plasma volume or
whether excessive production of erythropoietin also is involved as
is in the case of some human Bartter’s syndrome patients (5). In the
normal kidney, when a low Cl ion concentration is sensed by the
macula densa, two major changes occur: glomerular filtration is
increased, and renin is released from the adjacent juxtaglomerular
cells (17, 27, 34). All our data are compatible with this Cl-sensing
mechanism being disabled in the NKCC22y2 mice, so that the
macula densa cells transmit the signal that normally results from a
very low Cl ion concentration in the luminal fluid.
The most striking physiological abnormality in the surviving
2y2 mice at 3 months of age is the increased volume of their
urine (equivalent to 30 liters of urineyday in a 60-kg human),
which has an osmolality approaching that of plasma, indicating
a virtually complete lack of ability to concentrate urine (Table
3). Deprivation of drinking water for 12 h induced a loss of
more than 20% of body weight in the 2y2 mice. However,
despite this volume depletion, the urine osmolality did not rise,
and eventually the mice became anuric, suggesting that the
mutants can no longer respond to antidiuretic signals. We
tested this possibility by administration of an antidiuretic
hormone analogue, [desamino-Cys1, D-Arg8] vasopressin
(1 ngyg, i.p.). This treatment did not increase the urine
osmolality of the 2y2 mice (405 6 23 mOsm versus 395 6 20
mOsm in untreated 2y2 control, n 5 5), although it doubled
the osmolality (1,390 6 220 mOsm to 2,630 6 130 mOsm,
n 5 4, P , 0.005) in wild-type mice. The simplest explanation
of the failure of the 2y2 mice to respond to the vasopressin
analogue or to water deprivation is their inability to set up a
renal osmotic gradient combined with the damage to the
kidney medulla caused by their hydronephrosis.
A gross deficit in the ability of the NKCC22y2 mice to
concentrate their urine is not unexpected in view of the unique
location of the NKCC2 on the luminal surface of the thick
ascending limb cells (12, 13). Absence of transcellular NaCl
transport via NKCC2 also is expected to abolish the lumen
positive transepithelial voltage that enables paracellular reab-
sorption of Na and K across the wall of the tubule. The combined
absence of transcellular and paracellular transport of salt across
the thick ascending limb cells prevents the establishment of the
normal osmotic gradient necessary for urine concentration.
Urinary calcium excretion in the 2y2 mice was four times wild
type (Table 3) and was accompanied by calcification in renal
tubules (Fig. 2b). However, the plasma Ca concentration and the
food intake of the 2y2 mice were essentially the same as wild type.
In contrast, the plasma concentration and daily excretion of mag-
nesium of the 2y2 mice were not significantly different from wild
type. PGE2 excretion was more than twice normal.
In contrast to the 7-day-old mice, which often had no detectable
proteinuria, the surviving 2y2 adult mice excreted high amounts
of a low molecular mass protein ('20 kDa, Fig. 2c) in their urine
with males excreting four times more protein than females (Table
3). The molecular size of the protein and the gender difference
suggest that it is the mouse major urinary protein (MUP) (35). A
Western blot with an antibody against MUP confirmed this iden-
tification (data not shown). MUP is produced mainly in the adult
liver (36) and is excreted in the urine where it relates to sexual
communication. MUP production is known to be increased by
testosterone and growth hormone (37), but we are unaware of any
published description of the relationship between MUP and di-
uretics or hydronephrosis. The mechanism leading to the increased
proteinuria in the 2y2 mice is not clear. If it were because of
glomerular damage, a higher amount of albumin excretion would be
expected. Moreover, the 2y2 adult mice had at most only a trace
amount of hematuria, and transmission electron microscopy of their
glomeruli showed no noticeable morphological changes in the
glomerular basement membranes, podocytes, and endothelial cells
(data not shown). The proteinuria is therefore unlikely to be caused
by glomerular damage. The fact that the rat MUP homologue,
a2u-globulin, is a marker for low molecular weight protein reab-
Table 2. Blood data of adult mice
NKCC2 genotype
1y1 2y2
pH 7.30 6 0.01 7.42 6 0.01*
HCO3, mmolyliter 24.5 6 1.4 30.6 6 1.3†
Base excess, mmolyliter 22.5 6 0.9 4.9 6 0.6*
Lactate, mmolyliter 2.0 6 0.4 2.2 6 0.3
pCO2, mmHg 42.6 6 3.6 48.2 6 1.2
Glucose, mgydl 199.6 6 12.4 200.6 6 11.6
Hematocrit, % 37.0 6 3.2 70.0 6 0.3*
Na, mmolyliter 145.2 6 0.6 154.8 6 2.9†
K, mmolyliter 5.8 6 0.3 4.6 6 0.1†
Ca, mgydl 9.8 6 0.7 9.1 6 1.4
Creatinine, mgydl 0.15 6 0.05 0.23 6 0.09
PRC, ng Ang Iyml per h 32.4 6 5.0 751.3 6 76.8‡
Mice were 3 months old and treated with indomethacin to 3 weeks of age.
pCO2, CO2 pressure; PRC, plasma renin concentration. Data are means 6 SEM.
n . 5.
*P vs. 1y1 , 0.0005.
†P vs. 1y1 , 0.05.
‡P vs. 1y1 , 0.0001.
Table 3. Water intake and urine excretion of adult mice
NKCC2 genotype
1y1 2y2
Water intake, mlyday 3.3 6 0.2 13.2 6 1.0*
Urine volume, mlyday 1.6 6 0.2 10.0 6 0.9*
Urine osmolality, mOsm 2,314 6 74 371 6 20*
Na, mmolyday 118.2 6 19.8 119.4 6 14.9
K, mmolyday 378.2 6 14.4 415.3 6 23.9
Cl, mmolyday 274.6 6 23.4 301.4 6 20.1
Ca, mgyday 0.12 6 0.03 0.51 6 0.08†
Mg, mgyday 0.31 6 0.04 0.52 6 0.19
Pi, mgyday 1.95 6 0.11 3.39 6 0.20†
Glucose, mgyday 0.55 6 0.09 3.13 6 0.83‡
Protein (males), mgyday 0.17 6 0.03 10.10 6 0.51*
Protein (females), mgyday N.D. 2.68 6 0.15*
PGE2, ngyday 4.0 6 1.0 9.6 6 1.2*
Mice were 3 months old and treated with indomethacin to 3 weeks of age.
N.D., not detected (below detectable level).
Data are means 6 SEM. n . 5.
*P vs. 1y1 , 0.0001.
†P vs. 1y1 , 0.001.
‡P vs. 1y1 , 0.005.











sorption in the proximal tubules (38) suggests that the NKCC22y2
mice have an impaired ability of proximal tubule reabsorption.
Drug Treatments of the 2y2 Mice. Because nonsteroidal anti-
inflammatory drugs or the inhibition of renin Ang system
ameliorate the symptoms of human patients with Bartter’s
syndrome, we tested the effects of several drugs known to alter
renal function. Readministration of indomethacin (5 mgyg per
day) to the surviving 2y2 mice did not ameliorate their polyuria
or their daily urine volume, urinary Ca, and protein excretion.
Similarly, oral administration of an Ang II type 1 receptor
antagonist losartan (10 mgyg per day) or of an Ang-converting
enzyme inhibitor enalapril (5 mgyg per day) in drinking water for
1 week did not significantly change the daily urine volume or
urinary excretion of Ca or of protein by the surviving 2y2 mice,
although the drugs at these doses both decrease systolic blood
pressure of wild-type mice by 10–15 mmHg.
Phenotype of Furosemide-Treated Wild-Type Mice. Because the phe-
notype of the 2y2 mice is likely to be affected by their severe
hydronephrosis, we compared their phenotype with that of
wild-type animals given a NaK2Cl transport inhibitor furo-
semide in their drinking water from 4 weeks of age (100 mgyg
per day) for 4 weeks. This dose caused a urine output in 1y1
mice comparable to that in the NKCC22y2 mice and induced
a remarkably high plasma renin concentration of 4,600 6 68 ng
Ang Iyml per h; this renin concentration was more than six times
that in the 2y2 adults, presumably because the kidneys of the
furosemide-treated wild-type mice were minimally damaged
compared with those of the 2y2 mice. Indomethacin decreased
the plasma renin concentration of the furosemide-treated mice
to 430 6 31 ng Ang Iyml per h. The furosemide-treated mice
developed mild hydronephrosis, but almost no tissue damage was
observed. Therefore the gross effects of the hydronephrosis are
virtually eliminated. Nevertheless the amount of daily urinary
protein excretion in the furosemide-treated mice (9.5 6 0.7
mgyday in males and 2.3 6 0.3 mgyday in females, n 5 6) was
indistinguishable from that observed in the 2y2 mice. Again
most of the protein was '20 kDa in size, as in the 2y2 surviving
mice (data not shown). However, unlike the 2y2 mice, the
furosemide-treated mice responded, although weakly, to the
vasopressin analogue by changing their urine osmolality from
490 6 40 mOsm to 670 6 40 mOsm (n 5 7, P , 0.01). The
residual response in the furosemide-treated wild-type mice
suggests that they can still set up an osmotic gradient, although
much attenuated, which can be exploited by their relatively
undamaged medulla. Losartan, enalapril, or indomethacin, as in
the 2y2 mice, did not influence urine volume, Ca or protein
excretion of the furosemide-treated mice. These observations
suggest that the impaired ability of the NKCC22y2 mice and
the furosemide-treated wild-type mice to concentrate urine is so
overwhelming that correction of the concomitant disturbances in
the renin-Ang system is insufficient to affect the phenotype.
Thus, most of the results seen in the 2y2 adults can be
reproduced in an NKCC2-inhibited wild-type kidney that has
minimal damage, as judged by the recovery of renal function
when the furosemide treatment was stopped. Twenty four hours
after stopping the furosemide treatment, the urine volume had
fallen from 8.5 6 0.8 mlyday (about 5 times normal), to 3.1 6
0.3 mlyday (about 2 times normal), the osmolality had increased
from 490 6 40 mOsm, to 1430 6 150 mOsm (about 0.6 times
normal), and the urine protein had decreased from 4.0 6 0.5
mgyday to 1.1 6 0.1 mgyday, although this is still approximately
10 times higher than normal. Urine Ca excretion was reduced to
an undetectable level. Four weeks after stopping furosemide, all
urinary parameters including volume, osmolality, Ca, and pro-
tein had completely returned to normal, although a mild hydro-
nephrosis remained.
Comparisons with Human Patients. Much of the complex phenotype
of the NKCC22y2 mice is similar to that of human patients with
Bartter’s syndrome. Like humans with Bartter’s syndrome, sur-
viving NKCC22y2 mice exhibit lower plasma potassium and
higher bicarbonate, polyuria, hypercalciuria, nephrocalcinosis,
hyperreninemia, and elevated urinary PG. As mentioned above,
all of these alterations can be linked to the absence of NKCC2
in the thick ascending limb of Henle’s loop, where under normal
conditions approximately 30% of the filtered load of NaCl is
reabsorbed, and to the absence of NKCC2 in macula densa cells,
which regulate GFR and renin secretion.
Some features of the 2y2 mouse phenotype appear to
represent a species difference. The marked proteinuria of the
adult 2y2 mice falls into this category, because it involves the
increased urinary excretion of a small molecular size protein,
MUP, which is not present in human urine.
In contrast, most of the other differences between the two
species appear to be quantitative rather than qualitative. Such
differences include the following:
(i) Hydronephrosis is observed occasionally in human patients
although it is not usually severe as in the NKCC22y2 mice. We
presume that hydronephrosis arises in both species in response to
the back pressure produced by the polyuria, and that the differences
in severity of polyuria correlate with the severity of the hydrone-
phrotic process. Human kidneys are more mature at birth than
murine kidneys, although both continue to develop after birth. The
immaturity of the neonatal kidney may contribute to the more
severe hydronephrosis seen in mice compared with humans. In
support of this, we note that furosemide started at birth in wild-type
mice causes more severe hydronephrosis than when started at 4
weeks of age (unpublished observation).
(ii) The renal insufficiency and death of the NKCC22y2 pups
involve not only their impaired renal conservation of water and
electrolytes but also their failure to get sufficient milk to correct
the dehydration and to allow normal growth. Human patients
with Bartter’s syndrome display similar problems in the absence
of adequate fluid intake (23, 39).
(iii) Hypokalemia in the NKCC22y2 mice is unexpectedly
mild, whereas human patients with Bartter’s syndrome have
profound hypokalemia. Mice could be less susceptible to hypo-
kalemia because the amount of dietary potassium relative to
sodium is several times higher in mice compared with humans.
An impairment of distal tubular function to exchange Na and K
because of hydronephrosis also might be involved.
SummaryyConclusions. The NKCC22y2 pups exhibit renal in-
sufficiency, metabolic acidosis, and bilateral hydronephrosis and
die before weaning probably because they cannot get enough
milk. Indomethacin treatment during the sucking period helps
growth and rescues about 10% of the homozygotes. As adults,
the surviving 2y2 mice show lower plasma K, higher plasma
HCO3, and an above-normal pH, extreme polyuria and hydro-
nephrosis, hypercalciuria, and proteinuria. Their kidney param-
eters, like those of furosemide-treated wild-type mice with only
mild hydronephrosis, are unresponsive to inhibitors of the renin
Ang system, vasopressin, and readministration of indomethacin.
Thus absence of NKCC2 in the mouse causes a polyuria as a
result of impaired reabsorption of NaCl across renal epithelial
cells of the thick ascending limb and the macula densa that
cannot be compensated elsewhere in the nephron.
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